个人及工作简介：
医学博士，助理研究员，西安交通大学硕士研究生导师，《BMC cancer》审稿人，主要从事泌尿系肿瘤及尿道修复重建领域的基础研究及临床工作。2015年9月－2018年8月以访问学者身份赴美国肯塔基大学markey cancer center学习。主持国家自然科学基金2项，西安交通大学第一附属医院院基金1项。
研究领域：1.泌尿系肿瘤微环境；2.泌尿系肿瘤代谢重编程；3.泌尿系肿瘤耐药机制
主持科研项目：
1.国家自然科学基金面上项目，81872093，肥大细胞在高糖环境促进肾癌进展中的作用及机制研究，2019/01-2022/12，58万元。
2.国家自然科学基金青年基金，81302227，Adrenomedullin 在表浅性膀胱癌复发中的作用及机制——基于血管内皮细胞介导的化疗后肿瘤生长的研究，2014/01-2017/12，23万元。
3.西安交通大学第一附属医院院基金，高糖环境通过肥大细胞促进肾癌血管形成及治疗抵抗：PKM2介导的代谢重编程和炎症信号通路激活。2017/11-2020/06, 8万元。
代表性科研论文：
[1] Y. Chen, C. Li, H. Xie, Y. Fan, Z. Yang, J. Ma, D. He, L. Li, Infiltrating mast cells promote renal cell carcinoma angiogenesis by modulating PI3K-->AKT-->GSK3beta-->AM signaling, Oncogene, 36 (2017) 2879-2888.(IF=6.85)
[2] J. Liu, Z. Duan, W. Guo, L. Zeng, Y. Wu, Y. Chen, F. Tai, Y. Wang, Y. Lin, Q. Zhang, Y. He, J. Deng, R.L. Stewart, C. Wang, P.C. Lin, S. Ghaffari, B.M. Evers, S. Liu, M.M. Zhou, B.P. Zhou, J. Shi, Targeting the BRD4/FOXO3a/CDK6 axis sensitizes AKT inhibition in luminal breast cancer, Nature communications, 9 (2018) 5200. (IF=11.88)
[3] Y. Chen, G. Zhu, K. Wu, Y. Gao, J. Zeng, Q. Shi, P. Guo, X. Wang, L.S. Chang, L. Li, D. He, FGF2-mediated reciprocal tumor cell-endothelial cell interplay contributes to the growth of chemoresistant cells: a potential mechanism for superficial bladder cancer recurrence, Tumour biology : the journal of the International Society for Oncodevelopmental Biology and Medicine, 37 (2016) 4313-4321. (IF=3.65)
[4] Y. Chen, L. Zhang, X. Lu, K. Wu, J. Zeng, Y. Gao, Q. Shi, X. Wang, L.S. Chang, D. He, Sinomenine reverses multidrug resistance in bladder cancer cells via P-glycoprotein-dependent and independent manners, Die Pharmazie, 69 (2014) 48-54. (IF=1.05)
[5] Y. Chen, L. Li, J. Zeng, K. Wu, J. Zhou, P. Guo, D. Zhang, Y. Xue, L. Liang, X. Wang, L.S. Chang, D. He, Twist confers chemoresistance to anthracyclines in bladder cancer through upregulating P-glycoprotein, Chemotherapy, 58 (2012) 264-272. (IF=1.82)
[6] W. Song, D. He, Y. Chen, C.R. Yeh, I. Hsu, Q. Huang, X. Zhang, L.S. Chang, L. Zuo, J. Chen, K.M. Doersch, C. Chang, L. Li, S. Yeh, Targeting newly identified ERbeta/TGF-beta1/SMAD3 signals with the FDA-approved anti-estrogen Faslodex or an ERbeta selective antagonist in renal cell carcinoma, Molecular oncology, 12 (2018) 2055-2071. (IF=4.19)
[7] K. Wu, J. Fan, L. Zhang, Z. Ning, J. Zeng, J. Zhou, L. Li, Y. Chen, T. Zhang, X. Wang, J.T. Hsieh, D. He, PI3K/Akt to GSK3beta/beta-catenin signaling cascade coordinates cell colonization for bladder cancer bone metastasis through regulating ZEB1 transcription, Cellular signalling, 24 (2012) 2273-2282. (IF=4.19)
[8] K. Wu, Z. Ning, J. Zeng, J. Fan, J. Zhou, T. Zhang, L. Zhang, Y. Chen, Y. Gao, B. Wang, P. Guo, L. Li, X. Wang, D. He, Silibinin inhibits beta-catenin/ZEB1 signaling and suppresses bladder cancer metastasis via dual-blocking epithelial-mesenchymal transition and stemness, Cellular signalling, 25 (2013) 2625-2633. (IF=4.19)
[9] K. Wu, B. Wang, Y. Chen, J. Zhou, J. Huang, K. Hui, J. Zeng, J. Zhu, K. Zhang, L. Li, P. Guo, X. Wang, J.T. Hsieh, D. He, J. Fan, DAB2IP regulates the chemoresistance to pirarubicin and tumor recurrence of non-muscle invasive bladder cancer through STAT3/Twist1/P-glycoprotein signaling, Cellular signalling, 27 (2015) 2515-2523. (IF=4.19)
[10] J. Zeng, Y. Sun, K. Wu, L. Li, G. Zhang, Z. Yang, Z. Wang, D. Zhang, Y. Xue, Y. Chen, G. Zhu, X. Wang, D. He, Chemopreventive and chemotherapeutic effects of intravesical silibinin against bladder cancer by acting on mitochondria, Molecular cancer therapeutics, 10 (2011) 104-116. (IF=5.23)
[11] F. Li, Z. Ma, Z. Guan, Y. Chen, K. Wu, P. Guo, X. Wang, D. He, J. Zeng, Autophagy induction by silibinin positively contributes to its anti-metastatic capacity via AMPK/mTOR pathway in renal cell carcinoma, Int J Mol Sci, 16 (2015) 8415-8429. (IF=3.26)
[12] J. Zhou, Z. Deng, Y. Chen, Y. Gao, D. Wu, G. Zhu, L. Li, W. Song, X. Wang, K. Wu, D. He, Overexpression of FABP7 promotes cell growth and predicts poor prognosis of clear cell renal cell carcinoma, Urologic oncology, 33 (2015) 113.e119-117. (IF=2.92)
联系方式：
手机：13572538741（请发短信）
邮箱：cylxdwyd@126.com
